Perrigo Company (PRGO) Stock Price
Perrigo Company Price
Revenue has compounded at 5.8% per year over the past 19 years to 4.25 B USD. Earnings per share have grown at 2.3% per year over the last 13 years. Perrigo Company's net margin stands at -33.5%, down from -1.7% several years earlier. Perrigo Company currently offers a dividend yield of about 8.13%. The dividend has grown at 10.6% per year over the past 19 years. Analysts set a median price target of 36.00 USD, implying 152.5% above the current price. Of 10 analysts, 6 rate the stock a buy — an overall Buy consensus.
Perrigo Company stock price
Perrigo Company business model & stock analysis
Frequently asked questions about Perrigo Company
Perrigo Company PLC's business model revolves around developing, manufacturing, and distributing affordable healthcare products to improve the quality of life of consumers worldwide. By leveraging their expertise in over-the-counter (OTC) medications, health and wellness products, and generic prescription drugs, Perrigo aims to make healthcare more accessible and cost-effective. They focus on discovering innovative solutions, ensuring product quality, and maintaining strong partnerships with retailers and healthcare professionals. Perrigo's commitment to providing high-quality, affordable healthcare options positions them as a leading global provider in the industry.
Perrigo Company PLC is primarily active in the healthcare and pharmaceutical industries.
The main competitors of Perrigo Company PLC in the market include well-established pharmaceutical companies such as Johnson & Johnson, GlaxoSmithKline, Sanofi, and Novartis. These companies operate within similar market segments and offer a range of healthcare and consumer products, including over-the-counter medications, prescription drugs, and personal care items. Despite facing competition from these industry giants, Perrigo Company PLC has established itself as a key player in the global healthcare market, leveraging its expertise in manufacturing and distribution to provide high-quality, affordable products to customers worldwide.
Perrigo Company PLC is a leading healthcare company specializing in the production of over-the-counter pharmaceuticals and consumer goods. Established in 1887, Perrigo initially started as a packager of home remedies. Over time, it expanded its product offerings and global footprint through organic growth and strategic acquisitions. Today, Perrigo holds a strong position in the healthcare market, manufacturing a wide range of consumer healthcare products, such as vitamins, nutritional supplements, generic pharmaceuticals, and baby formula. With a solid history spanning over a century, Perrigo continues to innovate and deliver high-quality products that meet the evolving needs of customers worldwide.
Perrigo Company PLC has achieved significant milestones in its history. The company successfully completed the acquisition of Elan Corporation in 2013, expanding its offerings in the global pharmaceutical industry. In 2015, Perrigo acquired Omega Pharma, a leading European over-the-counter healthcare company, further strengthening its position in the market. Additionally, the company gained FDA approval for its generic version of Nexium, a popular heartburn medication, in 2018. Perrigo's continued commitment to innovation and strategic acquisitions has propelled its growth and cemented its position as a key player in the healthcare industry.
Perrigo Company PLC, a renowned global healthcare company, primarily operates in various countries and regions worldwide. Its strong presence extends across North America, Europe, and other key international markets. With a commitment towards providing affordable, high-quality healthcare products, Perrigo serves customers in the United States, Canada, the United Kingdom, Ireland, Germany, Spain, Italy, France, Belgium, the Netherlands, and other countries. By leveraging its robust distribution network and extensive market reach, Perrigo offers its comprehensive portfolio of over-the-counter medications, infant nutrition, and generic prescription products across these regions, ensuring accessibility and improved health outcomes for consumers globally.
Perrigo Company PLC represents values of excellence, integrity, and creativity. With a strong emphasis on quality, Perrigo strives to provide affordable healthcare products, essential to improving the lives of millions worldwide. The company's corporate philosophy revolves around prioritizing the needs of consumers, fostering innovation, and delivering value-driven solutions. Perrigo's commitment to responsible business practices and sustainable growth further demonstrates their dedication to making a positive impact. As a leading global pharmaceutical company, Perrigo continues to prioritize customer satisfaction, efficient operations, and continuous improvement, ultimately positioning themselves as a trusted provider in the industry.
Analysts currently set an average price target of 36.20 USD for the Perrigo Company stock (median: 36.00 USD), implying +153.9 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the Perrigo Company stock: 6 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Perrigo Company to generate revenue of 4.05 B USD and earnings per share of 2.19 USD.
Converted at the current exchange rate, the Perrigo Company share trades at 12.68 EUR (14.26 USD).
The Perrigo Company share (PRGO) is listed on 6 stock exchanges, including: NYSE (PRGO), London (0Y5E.L), SIX (Zürich) (PRGO.SW), München (PIG.MU), Düsseldorf (PIG.DU).
The Perrigo Company PLC is a globally operating company that specializes in the manufacturing and marketing of high-quality consumer healthcare products. Perrigo serves customers in over 40 countries worldwide with a wide range of products and services. Perrigo's business model is focused on offering its customers a broad range of high-quality and affordable consumer healthcare products. The company relies on a variety of business areas to best serve its customers. An important area of Perrigo's business is the production of over-the-counter products (OTC). This includes a variety of health and personal care products, such as pain relievers, vitamins, dietary supplements, and allergy remedies. The company also offers medications for the treatment of colds and flu. Perrigo is also a major producer of generics and offers a wide range of generic versions of prescription medications. The company also manufactures various types of inhalation devices and accessories to assist people with respiratory problems or asthma. Another important business area for Perrigo is the production of cosmetics and skincare products. The company offers a wide range of skincare products, including facial cleansers, moisturizers, and anti-aging products. Hair care products, such as shampoos and conditioners, are also part of the product range. Perrigo aims to provide access to high-quality products at affordable prices. The company continuously invests in research and development to expand its product range and bring new innovative products to the market. With a strong focus on quality and customer orientation, the company strives for sustainable growth and success. Overall, Perrigo's business model is based on offering its customers products of the highest quality at competitive prices. The company relies on a wide range of business areas and offers a variety of products to best serve its customers. Through continuous investments in innovation and research, Perrigo aims for sustainable growth and success.
The expected revenue of Perrigo Company is 4.05 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Perrigo Company is 302.76 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Perrigo Company is currently 6.52. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Perrigo Company stock.
The price-to-sales ratio (P/S) of Perrigo Company is currently 0.49. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Perrigo Company stock.
The Eulerpool Quality Score for Perrigo Company is 1/10.
The ISIN of Perrigo Company is IE00BGH1M568. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Perrigo Company is A1XAEY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Perrigo Company is PRGO. The ticker symbol is used to trade Perrigo Company shares on the stock exchange.
Perrigo Company stock
Perrigo Company Peer Group
Perrigo Company Ticker
Perrigo Company FIGI
All fundamentals and in-depth analysis of Perrigo Company
Our stock analysis for Perrigo Company stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Perrigo Company. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.